Cargando…

Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients

Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xueli, Zhang, Hong, Shen, Bairong, Sun, Xiao-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628020/
https://www.ncbi.nlm.nih.gov/pubmed/31207989
http://dx.doi.org/10.3390/ijms20122919
_version_ 1783434868487618560
author Zhang, Xueli
Zhang, Hong
Shen, Bairong
Sun, Xiao-Feng
author_facet Zhang, Xueli
Zhang, Hong
Shen, Bairong
Sun, Xiao-Feng
author_sort Zhang, Xueli
collection PubMed
description Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer.
format Online
Article
Text
id pubmed-6628020
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66280202019-07-23 Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients Zhang, Xueli Zhang, Hong Shen, Bairong Sun, Xiao-Feng Int J Mol Sci Article Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer. MDPI 2019-06-14 /pmc/articles/PMC6628020/ /pubmed/31207989 http://dx.doi.org/10.3390/ijms20122919 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Xueli
Zhang, Hong
Shen, Bairong
Sun, Xiao-Feng
Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
title Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
title_full Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
title_fullStr Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
title_full_unstemmed Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
title_short Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
title_sort chromogranin-a expression as a novel biomarker for early diagnosis of colon cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628020/
https://www.ncbi.nlm.nih.gov/pubmed/31207989
http://dx.doi.org/10.3390/ijms20122919
work_keys_str_mv AT zhangxueli chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients
AT zhanghong chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients
AT shenbairong chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients
AT sunxiaofeng chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients